Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated to v3.5.0, replacing v3.4.3. This appears to be an internal version update with no changes to the study content.SummaryDifference0.1%

- Check41 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedThe revision label was updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check77 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria are indicated.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a 'Show glossary' option, introduced the label 'Last Update Submitted that Met QC Criteria' (changing from 'Last Update Submitted that met QC Criteria'), and adjusted capitalization for 'No FEAR Act Data'. The site revision was updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.